Gilead Sciences (GILD) Tops Q1 EPS by 15c, Reiterate Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. MRVL
2. ZS
3. PENG
4. MSFT
5. NVDA
6. STZ
7. SPY
8. SKYD
9. IBM
10. CRWV

May 2, 2019 4:02 PM EDT

Gilead Sciences (NASDAQ: GILD) reported Q1 EPS of $1.76, $0.15 better than the analyst estimate of $1.61. Revenue for the quarter came in at $5.3 billion versus the consensus estimate of $5.3 billion.

  • Full Year 2019 Guidance Reiterated

Gilead reiterates its full year 2019 guidance, initially provided on February 4, 2019. The guidance for product sales reflects the anticipated entry of generic versions of Letairis and Ranexa in the United States and the full year impact of generic products containing tenofovir disoproxil fumarate in certain European countries.

(In millions, except percentages and per share amounts)�Initially Provided
February 4, 2019
Net Product Sales $21,300 - $21,800
Non-GAAP
Product Gross Margin 85% - 87%
R&D Expenses $3,600 - $3,800
SG&A Expenses $3,900 - $4,100
Effective Tax Rate 20.0% - 21.0%
Diluted EPS Impact of Acquisition-related, Up-front Collaboration, Stock-based Compensation and Other Expenses $1.40 - $1.50

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Hot Earnings

Related Entities

Earnings